High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Identifying the impact of a patient’s ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study. Methods: The clinical data of 272 treatment-naïve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy. Results: For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis (P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients (P=0.18). For patients with HCV genotype 2,the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis (P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively (P<0.01 for each). Korean patients with CHC achieved high SVR rates with peginterferon alfa-2a plus ribavirin in both the clinical trial and clinical practice settings. Conclusions: Measures to raise adherence to standard therapy in clinical practice may improve the SVR rates in these patients as effectively as adding protease inhibitors, thus obviating the need for the latter. (Clin Mol Hepatol 2013;19:60-69)
Abstract
Background/Aims: Identifying the impact of a patient’s ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study. Methods: The clinical data of 272 treatment-naïve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy. Results: For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis (P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients (P=0.18). For patients with HCV genotype 2,the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis (P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively (P<0.01 for each). Korean patients with CHC achieved high SVR rates with peginterferon alfa-2a plus ribavirin in both the clinical trial and clinical practice settings. Conclusions: Measures to raise adherence to standard therapy in clinical practice may improve the SVR rates in these patients as effectively as adding protease inhibitors, thus obviating the need for the latter. (Clin Mol Hepatol 2013;19:60-69)
참고문헌 (37)
- Lavanchy D, "The global burden of hepatitis C", Liver Int, 29(Suppl 1), pp.74~81 (2009)
- Shepard CW, "Global epidemiology of hepatitis C virus infection", Lancet Infect Dis, 5, pp.558~567 (2005)
- WHO, "Hepatitis C: global prevalence", Wkly Epidemiol Rec, 72, pp.341~344 (1997)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Hadziyannis SJ, "Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
- Jacobson IM, "Telaprevir for previously untreated chronic hepatitis C virus infection", N Engl J Med, 364, pp.2405~2416 (2011)
- Poordad F, "Boceprevir for untreated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1195~1206 (2011)
- Ge D, "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance", Nature, 461, pp.399~401 (2009)
- Thomas DL, "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus", Nature, 461, pp.798~801 (2009)
- Tanaka Y, "Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C", Nat Genet, 41, pp.1105~1109 (2009)
- Dev AT, "Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome", Hepatology, 36, pp.1259~1265 (2002)
- Hepburn MJ, "Differences in treatment outcome for hepatitis C among ethnic groups", Am J Med, 117, pp.163~168 (2004)
- Missiha S, "Canadian Pegasys Expanded Access Group. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C", Am J Gastroenterol, 102, pp.2181~2188 (2007)
- Yan KK, "Treatment responses in Asians and Caucasians with chronic hepatitis C infection", World J Gastroenterol, 14, pp.3416~3420 (2008)
- Hu KQ, "Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial", J Clin Gastroenterol, 45, pp.720~726 (2011)
- Vutien P, "Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C", Am J Gastroenterol, 105, pp.1110~1115 (2010)
- Nguyen NH, "Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2", 3 vs 6, 2010, pp.17, 691~697
- Lawson A, "A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients", J Viral Hepat, 18, pp.e270~e277 (2011)
- Freshwater DA, "Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy", J Viral Hepat, 15, pp.115~119 (2008)
- Feuerstadt P, "Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients", Hepatology, 51, pp.1137~1143 (2010)
- Lindor RA, "The value of observational research in liver diseases", Hepatology, 53, pp.1~3 (2011)
- Pariente A, "Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in ‘true life’: a plea in favor of independent postmarketing evaluations", Eur J Gastroenterol Hepatol, 22, pp.1297~1302 (2010)
- Shehab TM, "Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice", Clin Gastroenterol Hepatol, 2, pp.425~431 (2004)
- Lo Re V 3rd, "Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study", Ann Intern Med, 155, pp.353~360 (2011)
- Marotta P, "Efficacy of chronic hepatitis C therapy in community-based trials", Clin Gastroenterol Hepatol, 7, pp.1028~1036 (2009)
- Howell CD, "Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1", J Hepatol, 56, pp.557~563 (2012)
- Sinn DH, "Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients", J Gastroenterol Hepatol, 26, pp.1374~1379 (2011)
- Lyoo K, "Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin", J Clin Virol, 52, pp.363~366 (2011)
- Sievert W, "A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt", Liver Int, 31(Suppl 2), pp.61~80 (2011)
- Oh HB, "Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 5’ untranslated region using a matrix assisted laser desorption", ionization time of flight-based assay, restriction fragment mass polymorphism, 2008, pp.80, 1712~1719
- McHutchison JG, "Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C", Gastroenterology, 123, pp.1061~1069 (2002)
- Reddy KR, "Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a", ribavirin treatment, 2007, pp.5, 124~129
- Shiffman ML, "Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C", Gastroenterology, 132, pp.103~112 (2007)
- Weiss JJ, "Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research", Aliment Pharmacol Ther, 30, pp.14~27 (2009)
- Raptopoulou M, "The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients", J Viral Hepat, 12, pp.91~95 (2005)
- Clark CH, "Hepatitis C: role of the advanced practice nurse", AACN Clin Issues, 10, pp.455~463 (1999)